One-two punch of drugs better than either alone against colorectal cancer

Commonly, mutations or rearrangements of genes in the MAPK signaling pathway create cancer’s fast growth, and alterations in the PI3K signaling pathway allow cancer cells to survive into virtual immortality. Of course, researchers have extensively targeted these two signaling pathways, designing drugs that turn on or off genes in these pathways, thus interrupting the transmission of cancer-causing signals. Unfortunately, these pathways have proven difficult to drug and also it has been difficult to show the effectiveness of drugs that successfully interrupt the transmission of signals along these pathways. A study by the University of Colorado Cancer Center published in the journal PLoS ONE and concurrent phase I clinical trial is examining a new strategy: targeting both these important cancer-causing pathways simultaneously. Read more here.